anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
To analyze the clinical characteristics of appendiceal orifice polyps and the effect of endoscopic super minimally invasive treatment. A retrospective analysis was conducted on the general situation (age and sex), the classification of appendiceal orifice polyps, the treatment method under endoscope, postoperative pathology and postoperative complications in patients who underwent resection of appendiceal orifice polyps at the Peking University First Hospital and the First Medical Center of the PLA General Hospital from January 1, 2022, to December 31, 2023. A total of 47 patients were included, consisting of 28 males and 19 females, with 35-86 (61±12) years. Appendiceal orifice polyps were classified into four types: type 0 (14 cases), type 1 (15 cases), type 2 (12 cases), and type 3 (6 cases). Among the endoscopic morphologies, 22 cases were granular laterally spreading tumors. Endoscopic mucosal dissection was performed in 37 cases. Postoperative appendiceal stent placement was performed in 1 case. The pathological types of polyps included adenoma in 15 cases, high-grade intraepithelial neoplasia in 10 cases, intramucosal carcinoma in 4 cases, submucosal carcinoma in 5 cases, inflammatory polyps in 1 cases, and sessile serrated lesion in 12 cases. Curative resection was performed in 44 cases. There were no postoperative complications such as bleeding, perforation, or acute appendicitis. The pathology of appendiceal polyps is mostly precancerous lesions, and the treatment scheme of endoscopic super minimally invasive resection is both safe and effective.
The present invention relates to the use of cannabidiol (CBD) for the treatment of tumours associated with Tuberous Sclerosis Complex (TSC). Preferably, the TSC associated tumours are benign. Preferably, treatment with CBD reduces the size of the tumours. Preferably, the CBD is administered in combination with one or more concomitant drugs used in the treatment of TSC (e.g. an mTOR inhibitor, such as rapamycin or everolimus). CBD may be present as a purified extract of cannabis comprising at least 95 % (w/w) CBD. Preferably, the extract of cannabis comprises less than 0.15 % THC (tetrahydrocannibinol). Most preferably, the extract further comprises up to 1 % CBDV (cannabidivarin). CBD may be present as a synthetic compound. The dose of CBD used may be greater than 5 mg/kg/day. Also claimed is a method of treating a patient with TSC comprising administering CBD.
Epigenetic alterations play a crucial role in developmental processes, tissue regeneration, and cellular differentiation. Epigenetic changes are dynamically reversible. Various drugs that target DNA methyltransferases or histone deacetylases have demonstrated their ability to restore normal epigenetic patterns in a number of diseases. While the involvement of epigenetic modifications has been identified in chronic inflammatory diseases, their specific impact on skin inflammation in stromal cells remains unclear. This mini-review explores the role of stromal cells in chronic inflammatory skin diseases, focusing on epigenetic modifications of stromal cells such as fibroblasts, lymphatic, and blood vascular endothelial cells in both healthy and diseased skin. We also provide an overview of recent findings that highlight the contribution of stromal cells, including fibroblasts, to inflammatory and remodeling processes through epigenetic changes in the context of chronic inflammatory conditions. Investigating epigenetic reprogramming of stromal cells might lead to novel strategies for treating chronic inflammatory skin diseases. [BMB Reports 2024; 57(11): 465-471].
Anti-acid compositions comprise mixtures of calcium caseinate and calcium carbonate, e.g. in the proportions of 5 parts caseinate to 1 part carbonate.  This mixture may be obtained by reacting excess of calcium carbonate with casein.  Aluminium hydroxide, magnesium silicate, kaolin, charcoal, pectin may be added and the mixture may be in the form of a powder or tablet.  The Specification as open to inspection under Sect. 91 mentions admixtures of strontium and magnesium caseinates with calcium strontium, magnesium and bismuth carbonates.  This matter does not appear in the Specification as accepted.
<P>PROBLEM TO BE SOLVED: To provide homogeneous, semi-solid single-use beads of an oral, dental or skin hygienic composition.  <P>SOLUTION: The homogeneous, semi-solid single-use lumps or beads (200) are brought to be possibly produced by mixing a controlled amount of agar with a regular oral, dental or skin hygienic composition. Agar or analogous structure gelling agents make it possible to crush the bead on the skin or in the mouth without leaving residues with giving sufficient rigidity and a sufficiently high melting point for storage. Dental or skin care packs (600) hold sufficient beads and optionally a disposable brush. Blister packs (124) carry cast in-situ beads of one or various active components. Shape, color and flavor variations (124C) motivate children for dental care.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Patients receiving a quadrivalent inactivated influenza vaccine containing 15 µg of hemagglutinin (HA) for each of the 4 strains included. Suspension for injection is sterile liquid supplied in 0.5mL single dose pre-filled syringe. Vaccine is injected intra-muscularly in the non-dominant arm at Day 0.
FIELD: biotechnology, microbiology. SUBSTANCE: method involves leavening the nutrient medium, growing microorganisms in nutrient medium, separation of bacterial mass from cultural fluid, its mixing with protective medium and drying. For this purpose leavening the nutrient medium is carried out with pure cultures Bifidobacterium longum T-89, Bifidobacterium thermophilum TP-8, Lactobacillus acidophilus 97 and Ruminococcus flavefaciens K-399 that are added in the amount 10% to medium volume and the parent ratio of cultures is brought about to be = 3:3:1:3, respectively. The proposed method provides preparing a fodder supplement with high content of viable microflora cells. Invention can be used in animal husbandry for prophylaxis of gastrointestinal infections in calves and stimulation of their growth and development. EFFECT: improved preparing method. 1 ex
The present invention provides a fully automatic controlled system, employed for the synthesis of [18F]-FET (O-(2-[18F]fluoroethyl)-L-Tyrosine) which is mainly used for the diagnosis of tumor in brain. 18F is an artificial radioisotope with half-life of 109.8 minutes. [18F]FET is a fluorine labelled amino acid, known to be incorporated into newly synthesized proteins, rendering it a potentially suitable tracer to image protein metabolism in vivo using positron emission tomography. The synthesis process of[18F]FET include fluorination, evaporation, synthesis, hydrolysis, neutralization, separation and collection. In easy terms, the actual operation procedures of this system can be divided into three steps. First, put the raw material into designed reaction bottle, afterward, turn on power button and run the executive program. Fifty minutes after this program is started, [18F]FET can be produced for clinical applications.
FIELD: medicine, chemical-pharmaceutical industry. SUBSTANCE: ginseng leaves are milled to particle size 7 mm, extracted with water into electroimpulse extractive chamber at hydromodulus 1:20 and under effect of impact waves produced by impulse electric discharges width 1.2 ms, front is 5 ns. Impulse amount is 1400 in series, their amplitude is 20-36 kV, interelectrode interval is 1.75-2.25 mm. Raw is extracted three-fold with water at 20 C for 8 min, extracts are combined, concentrated under vacuum, treated with 3-fold volume of 96% ethanol in the ratio extractant : ethanol = 1:3. Water-soluble polysaccharides are precipitated, precipitate is filtered off, washed out with ethanol and dried on the glass. EFFECT: increased yield of product, decreased process time, simplified method, enhanced effectiveness of method. 4 dwg, 4 tbl, 3 ex
<P>PROBLEM TO BE SOLVED: To provide nucleic acid molecules and proteins for identification, assessment, prevention, and therapy of ovarian cancer.  <P>SOLUTION: The invention relates to newly discovered nucleic acid molecules and proteins associated with ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human ovarian cancers are provided. The invention also relates to cancer markers, which are listed in Table 1. The invention provides nucleic acids and proteins that are encoded by or correspond to the markers. The invention further provides antibodies, antibody derivatives and antibody fragments which bind specifically with such proteins and/or fragments of the proteins.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Chronic myeloid leukemia (CML) is associated with the Philadelphia chromosome and distinct BCR::ABL1 gene transcripts. We assessed the frequencies of these transcripts in Mexico, Latin America, and worldwide. We determined the prevalence of BCR::ABL1 transcripts in CML patients and intercontinental or regional variations using specialized databases and keywords. We analyzed 34 studies from 20 countries, encompassing 5795 patients. Keyword-based searches in specialized databases guided data collection. ANOVA was employed for transcript distribution analysis. The b3a2 transcript was most prevalent globally, followed by b2a2, with e1a2 being the least frequent. Interestingly, Mexico City exhibited a higher incidence of b2a2, while b3a2 predominated in the remaining country. Overall, no significant intercontinental or regional variations were observed. b3a2 was the most common BCR::ABL1 transcript worldwide, with b2a2 following closely; e1a2 was infrequent. Notably, this trend remained consistent in Mexico. Evaluating transcript frequencies holds clinical relevance for CML management. Understanding the frequency of transcript informs personalized CML treatments.
Emergency surgeries are linked with increased morbidity and reduced life expectancy, often associated with low socioeconomic status, limited access to healthcare, and delayed hospital admissions. While the influence of socioeconomic status on elective surgery outcomes is well-established, its impact on emergency surgeries, including ostomy creation and closure, is less clear. This study aimed to explore how the pandemic and socioeconomic status affect emergency ostomy procedures, seeking to determine which has a greater effect. It emphasizes the importance of considering socioeconomic factors in patient care pathways for ostomy procedures. A total of 542 patients who underwent emergency ostomy formation between 2016 and 2022 were retrospectively analyzed and divided into pre-pandemic and pandemic periods. The pre-pandemic and pandemic periods were compared between themselves and against each other. Demographic data (age and sex), comorbidities, socioeconomic status, etiology of the primary disease, type of surgery, stoma type, length of hospital stay, ostomy closure time, and postoperative complications were retrospectively analyzed for all patients. In total, 290 (53%) patients underwent surgery during the pandemic period, whereas 252 (47%) underwent surgery during the pre-pandemic period. Emergency surgery was performed for malignancy in 366 (67%) patients. The number of days patients underwent ostomy closure was significantly higher in the low-income group (P = .038, 95% CI: 293,2, 386-945). The risk of failure of stoma closure was 3-fold (95% CI: 1.8-5.2) in patients with metastasis. The risk of mortality was 12.4-fold (95% CI: 6.5-23.7) when there was failure of stoma closure. When compared to pandemic period, the mortality risk was 6.3-fold (95% CI: 3.9-10.2) in pre-pandemic period. Pandemic patients had a shorter hospital stay than before the pandemic (P = .044). A high socioeconomic status was significantly associated with early hospital admission for ostomy closure, and lower probability of mortality. More metastases and perforations were observed during the pandemic period and mortality was increased during pandemic and in patients without ostomy closure. The socioeconomic status lost its effect in cases of emergency ostomy creation and had no impact on length of hospital stay in either the pre-pandemic or pandemic period.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely to parodontics, and can be used for treating periodontal abscess. That is ensured by antiseptic preparation of the oral cavity, anaesthesia, opening of abscess by blunt dissection, drug-induced management. Thereafter, a dental core in number 1 to 3 containing metronidazole, a dry Echnacea extract, and copolymer of styrene and maleic anhydride as a base in the ratio, wt % 10:10:80 is inserted in the periodontal pocket. ^ EFFECT: invention allows to eliminate inflammation in single dosage and to avoid undesired gum retraction and systemic administration of antibiotics. ^ 2 ex
BRIDION doses up to 16 mg/kg were associated with increases in the coagulation parameters activated partial thromboplastin time (aPTT) and prothrombin time/international normalized ratio [PT(INR)] of up to 25% for up to 1 hour in healthy volunteers.

In patients undergoing major orthopedic surgery of the lower extremity who were concomitantly treated with heparin or low molecular weight heparin for thromboprophylaxis, increases in aPTT and PT(INR) of 5.5% and 3.0%, respectively, were observed in the hour following BRIDION 4 mg/kg administration. This clinical trial did not demonstrate an increased blood loss or anemia incidence with BRIDION compared with usual treatment. The rate of adjudicated bleeding events within 24 hours was 2.9% for sugammadex and 4.1% for usual care. The rate of post-operative anemia was 21% for sugammadex and 22% for usual care. The mean 24-hour drainage volume was 0.46 L for sugammadex and 0.48 L for usual care. The need for any post-operative transfusion was 37% for sugammadex and 39% for usual care.

In vitro experiments demonstrated additional aPTT and PT(INR) prolongations for sugammadex in combination with vitamin K antagonists, unfractionated heparin, low molecular weight heparinoids, rivaroxaban, and dabigatran up to ~25% and ~50% at C max levels of sugammadex corresponding to 4 mg/kg and 16 mg/kg doses, respectively. 

Since bleeding risk has been studied systematically with only heparin and low molecular weight heparin thromboprophylaxis and 4 mg/kg doses of sugammadex coagulation parameters should be carefully monitored in patients with known coagulopathies, being treated with therapeutic anticoagulation, receiving thromboprophylaxis drugs other than heparin and low molecular weight heparin, or receiving thromboprophylaxis drugs and who then receive a dose of 16 mg/kg sugammadex.
Cohort of individuals found to have average sleep duration of \< 7 hours per night. Individuals who sleep on average less than 6 hours per night will further be sub-categorized as very short sleeprs.
The invention relates to a medicinal liquor for treatment of high uric acid. The medicinal liquor is characterized by comprising: 1000ml of 50-degree white spirit, 2000ml of water, 50g of soybeans, 50g of radix angelicae pubescentis, 30g of cortex dictamni, 30g of notopterygium, 20g of ginseng, 20g of Fructus Arctii, 20g of bighead atractylodes rhizome, 20g of Astragalus, 10g of fresh bamboo leaves, 10g of rhizoma imperatae, and 10g of angelica. The preparation method includes: putting the medicinal materials into a Chinese medicine pot, and adding water to conduct decoction for 30min, and pouring the remaining about 200ml of medicine into a measuring cup to cool for 30min, then blending the medicine with the white spirit, and carrying out filtering to remove the residue after 10 days, thus obtaining the medicinal liquor. 10-20ml of the medicinal liquor is taken orally every time during lunch and supper for 10 days as a course of treatment. The medicinal liquor provided by the invention solves the problems in existing traditional treatment methods for high uric acid, i.e. big risk of operation, large side effect of drugs, and slow effect of traditional Chinese medicine acupuncture and massage, and can treat high uric acid.
<P>PROBLEM TO BE SOLVED: To provide a gold fine particle structure in which a holding substance is bound to a gold nanorod through a linker; when a pigment or a medicine is used as the holding substance, the particle can be utilized in a fluorescence-emission method using the pigment or in a drug delivery system (DDS) in which the medicine is released to a specific site by the separation of the holding substance; and when PEG is used as the holding substance, the particle can be utilized in a method in which the gold nanorod is aggregated by the separation of PEG to detect the aggregated site, and to provide a method for producing the same.  <P>SOLUTION: The rod-shaped gold fine particle structure comprises a holding substance, a linker, and a rod-shaped gold fine particle. The holding substance is bound to the gold fine particle through the linker. A binding site between the holding substance and the linker is formed of a product of the Diels-Alder reaction. The reaction product has properties of being cut by the generation of heat by the thermal conversion of near-infrared light. The holding substance is separated from the gold particle by the cutting of the binding site. There are also provided a method for producing the same and applications thereof.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Topical diclofenac, will will be applied onto the skin of one arm, every day for 30 days. Enough medication will be used to cover an area of approximately 4 square inches( a 2 inch by 2 inch square). The medications will come in a tube. The medications will be applied to the same sun exposed site on the arm every day. The research team will provide instructions for the correct application of the treatment.
Compositions for treating bovine mastitis comprise a pharmaceutically inert gas, which may be a fluorinated hydrocarbon, having suspended per 50 to 3000 c.c. of gas, an effective dose of one or more medicaments in dry powder form, having a particle size of 0.005 to 5 microns.  Medicaments may be antibiotics such as penicillin, neomycin, bacitracin, streptomycin, dihydrostreptomycin, oxytetracycline, chlortetracycline, tetracycline, polymyxin, tyrothrium, orythromycin, oleandomycin, tylosin, colimycin and rifamycin; sulpha drugs such as sulphanilamide and sulphadiazine; nitrofurans such as nitrofurazone; quaternary ammonium compounds and corticosteroids.  Anticaking agents such as starch, lactose, or micronized silica may also be present.  The composition may be put up in a conventional aerosol container, or in a dispenser wherein the gas is discharged through a separate compartment containing the powdered medicament.  The composition is used by inflating the infected lactiferous sinus with the medicated gas (see Division A5).ALSO:Bovine mastitis is treated by inflating the infested bactiferous sinus with 50 to 3000 ccs. of a pharmacentically inert gas having in suspension an effective amount of one or more medicaments in dry powder form, the medicament having a particle size of 0.005 to 5 microns.  Preferred gases are carbon dioxide or nitrogen, suitably dispersed at an initial pressure of 90 lbs./sq. p inch: alternatively compressed air, or the fluorinated hydrocarbons may be used.  Suitable medicaments are antibiotics, such as penicillin, neomycin, bacitracin, streptomycin, dihydrostreptomycin, oxytetracycline, chlortetracycline, tetracycline, polymixin, tyrothrium, erythromycin, oleandomycin, tylosin, colimycin, and rifamycin; sulpha drugs such as sulphanilamide and sulphadiazine; nitrofurans such as nitrofurazone; quaternary ammonium compounds; and corticosteroids such as cortisone, hydrocortison, prednisone or prednisolone. Preferably included are anti-caking agents, such as micronised silica, starch, or lactose.  An example is given for a composition containing procaine-pencillin G, nitrofurazone and amorphous silica, dispensed by carbon dioxide at 90 lbs/sq. inch pressure.
Although it is generally assumed that face recognition relies on holistic processing, whether face recognition deficits observed in Developmental Prosopagnosics (DPs) can be explained by impaired holistic processing is currently under debate. The mixed findings from past studies could be the consequence of DP's heterogeneous deficit nature and the use of different measures of holistic processing-the inversion, part-whole, and composite tasks-which showed a poor association among each other. The present study aimed to gain further insight into the role of holistic processing in DPs. Groups of DPs and neurotypicals completed three tests measuring holistic face processing and non-face objects (i.e., Navon task). At a group level, DPs showed (1) diminished, but not absent, inversion and part-whole effects, (2) comparable magnitudes of the composite face effect and (3) global precedence effect in the Navon task. However, single-case analyses showed that these holistic processing deficits in DPs are heterogeneous.
Following intravenous administration of a single dose, the serum concentration profile of enalaprilat is polyexponential with a prolonged terminal phase, apparently representing a small fraction of the administered dose that has been bound to ACE. The amount bound does not increase with dose, indicating a saturable site of binding. The effective half-life for accumulation of enalaprilat, as determined from oral administration of multiple doses of enalapril maleate, is approximately 11 hours. Excretion of enalaprilat is primarily renal with more than 90 percent of an administered dose recovered in the urine as unchanged drug within 24 hours. Enalaprilat is poorly absorbed following oral administration.

The disposition of enalaprilat in patients with renal insufficiency is similar to that in patients with normal renal function until the glomerular filtration rate is 30 mL/min or less. With glomerular filtration rate ≤30 mL/min, peak and trough enalaprilat levels increase, time to peak concentration increases and time to steady state may be delayed. The effective half-life of enalaprilat is prolonged at this level of renal insufficiency. (See DOSAGE AND ADMINISTRATION.) Enalaprilat is dialyzable at the rate of 62 mL/min.

Studies in dogs indicate that enalaprilat does not enter the brain, and that enalapril crosses the blood-brain barrier poorly, if at all. Multiple doses of enalapril maleate in rats do not result in accumulation in any tissues. Milk in lactating rats contains radioactivity following administration of 14C enalapril maleate. Radioactivity was found to cross the placenta following administration of labeled drug to pregnant hamsters.
PURPOSE: An extract containing 85w/w% or more of anthocyanoside oligomers is provided with an excellent stability and an improving effect on the eyesight. Also, provided is a composition containing the same. CONSTITUTION: A composition of a preparation for ophthalmology contains 0.01-95.00 wt.% of an extract containing 85w/w% or more of anthocyanoside oligomers, and one or more kinds of pharmaceutical excipients. The extract is obtained by making an anthocyanosides-containing solution from the grape skins and a mixture of ethanol and water. The solution is then filtered, and concentrated. An anthocyanoside monomer extract is made from the concentrated solution. The anthocyanoside monomer extract then undergoes the processes of fermentation, ultrafiltration, and lyophilization.